Peter Blume-Jensen
2022
In 2022, Peter Blume-Jensen earned a total compensation of $21.7M as Chief Executive Officer, President and Director at Acrivon Therapeutics, a 2,765% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $469,700 |
|---|---|
| Option Awards | $1,951,598 |
| Salary | $535,942 |
| Stock Awards | $18,728,000 |
| Total | $21,685,240 |
Blume-Jensen received $18.7M in stock awards, accounting for 86% of the total pay in 2022.
Blume-Jensen also received $469.7K in non-equity incentive plan, $2M in option awards and $535.9K in salary.
Rankings
In 2022, Peter Blume-Jensen's compensation ranked 63rd out of 5,732 executives tracked by ExecPay. In other words, Blume-Jensen earned more than 98.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 63 out of 5,732 | 99th |
Division Manufacturing | 16 out of 3,121 | 100th |
Major group Chemicals And Allied Products | 8 out of 1,416 | 99th |
Industry group Drugs | 7 out of 1,317 | 100th |
Industry Pharmaceutical Preparations | 6 out of 963 | 99th |
Source: SEC filing on May 1, 2023.
Blume-Jensen's colleagues
We found two more compensation records of executives who worked with Peter Blume-Jensen at Acrivon Therapeutics in 2022.